Analysts Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Price Target at $829.65

Key Points

• Regeneron Pharmaceuticals has received a consensus analyst rating of "Moderate Buy", with 16 buy ratings, 3 strong buy ratings, and only 1 sell rating from 26 brokerages.
• The company's most recent earnings report showed an EPS of $12.89, significantly surpassing estimates and reflecting a year-over-year revenue increase of 3.6%.
• Regeneron announced a quarterly dividend of $0.88 per share, with a dividend yield of 0.6%, set to be paid on September 3rd.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the twenty-seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and three have issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $817.6667.

REGN has been the topic of several research analyst reports. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective on the stock. in a research report on Friday, August 1st. Guggenheim boosted their target price on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Argus downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Royal Bank Of Canada boosted their target price on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a research report on Monday, August 4th. Finally, UBS Group reiterated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Pinney & Scofield Inc. purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. raised its position in Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 31 shares during the period. Activest Wealth Management raised its position in Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 21 shares during the period. Costello Asset Management INC purchased a new stake in Regeneron Pharmaceuticals during the first quarter valued at approximately $27,000. Finally, Saudi Central Bank purchased a new stake in Regeneron Pharmaceuticals during the first quarter valued at approximately $27,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $3.00 on Tuesday, hitting $576.61. 268,188 shares of the company traded hands, compared to its average volume of 1,102,023. The company has a market capitalization of $61.11 billion, a price-to-earnings ratio of 14.54, a P/E/G ratio of 1.96 and a beta of 0.33. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The business's 50 day moving average price is $555.84 and its 200-day moving average price is $588.67. Regeneron Pharmaceuticals has a 52-week low of $476.49 and a 52-week high of $1,210.97.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. The company had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.Regeneron Pharmaceuticals's quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the previous year, the business earned $11.56 earnings per share. Equities analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.